C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R. de Wit,Christian Wülfing,Daniel Castellano,Gero Kramer,J.-C. Eymard,Cora N. Sternberg,Karim Fizazi,Karim Fizazi,Bertrand Tombal,Aristotle Bamias,Joan Carles,Roberto Iacovelli,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Theodore,Susan Feyerabend,Carole Helissey,M.C. Foster,Ayse Ozatilgan,Christine Geffriaud-Ricouard,J.S. de Bono,J.S. de Bono +22 more
TL;DR: In this article, the authors investigated neutrophil-to-lymphocyte ratio (NLR) as a biomarker for patients with metastatic castration-resistant prostate cancer (mCRPC).
Journal ArticleDOI
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Anuradha Jayaram,Anna Wingate,Daniel Wetterskog,Graham M. Wheeler,Cora N. Sternberg,Robert Jones,Alfredo Berruti,Florence Lefresne,Marjolein Lahaye,Shibu Thomas,Michael Gormley,F. Meacham,K. Garg,L.P. Lim,Axel S. Merseburger,Bertrand Tombal,Deborah Ricci,G. Attard +17 more
TL;DR: In this article, a second sample collected after one cycle of treatment could refine outcome prediction of patients identified as poor prognosis based on plasma DNA collected pre-treatment, which could improve risk stratification before commencing a new treatment.
Journal ArticleDOI
7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study
S. J. Harland,J.S. de Bono,C. M. Haqq,John Staffurth,Yanni Hao,Dennis D. Gagnon,Cameron S. Liu,Cora N. Sternberg,Ana M. Molina,Howard I. Scher +9 more
Journal ArticleDOI
A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.
TL;DR: This multicenter, 2-stage, open-label phase II trial will determine the safety and efficacy of dovitinib administered at a dose of 500 mg/day on a 5 days on/2 days off dosing schedule in advanced UC patients relapsed or refractory to standard first-line chemotherapy.
Journal ArticleDOI
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy
Ian F. Tannock,Cora N. Sternberg +1 more
TL;DR: Concern and disagreement are expressed with the (grade 1A) recommendation in the ESMO clinical practice guidelines for prostate cancer that: ‘androgen deprivation therapy (ADT) plus docetaxel is recommended as first-line treatment of metastatic, hormone-naïve disease in men fit enough for chemotherapy’.